StreetInsider.com News Articles

Form 4 Aquestive Therapeutics, For: Oct 21 Filed by: Cochran John

Fri, 23 Oct 2026 13:39:00 -0400

si-local-file:///var/storage/secattach/20261023/27227293.html

Form 8-K Aquestive Therapeutics, For: Oct 15

Mon, 19 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261019/27203835.html

Form 4 Aquestive Therapeutics, For: Oct 15 Filed by: Barber Daniel

Fri, 16 Oct 2026 14:17:00 -0400

si-local-file:///var/storage/secattach/20261016/27197552.html

Form 3 Aquestive Therapeutics, For: Oct 15 Filed by: Daly Richard J

Fri, 16 Oct 2026 13:58:00 -0400

si-local-file:///var/storage/secattach/20261016/27197480.html

H.C. Wainwright Reiterates Buy Rating on Aquestive Therapeutics (AQST)

Fri, 16 Oct 2026 08:07:56 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $10.00 price target on Aquestive Therapeutics (NASDAQ: AQST).

The analyst commented: 'This morning, Aquestive Therapeutics announced that the FDA has acknowledged its resubmission of the New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, as complete and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027, in keeping with the FDA’s classification of the resubmission as a Class 2 response. If approved, Anaphylm would be the first and only oral rescue medication for the treatment

Form 8-K Aquestive Therapeutics, For: Oct 15

Thu, 15 Oct 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20261015/27189622.html

FDA accepts Aquestive's Anaphylm NDA resubmission with March 2027 review date

Thu, 15 Oct 2026 07:00:35 -0400

Aquestive Therapeutics (NASDAQ: AQST) announced that the U.S. Food and Drug Administration has accepted the company's resubmission of the New Drug Application for Anaphylm (dibutepinephrine) sublingual film, a treatment candidate for Type I allergic reactions, including anaphylaxis.

The FDA classified the resubmission as a Class 2 response and assigned a Prescription Drug User Fee Act goal date of March 16, 2027. Aquestive submitted the resubmission on September 16, 2026, following positive topline results from human factors and pharmacokinetic studies conducted to address items raised in the FDA's Complete Response Letter issued January 30, 2026.

Anaphylm is a polymer matrix-based epinephrine prodrug delivered

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

Thu, 15 Oct 2026 07:00:00 -0400

FDA accepted the resubmission as complete and classified it as a Class 2 response
Prescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027
Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026

WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

Thu, 15 Oct 2026 07:00:00 -0400

FDA accepted the resubmission as complete and classified it as a Class 2 response
Prescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027
Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026

Form 8-K Aquestive Therapeutics, For: Oct 13

Wed, 14 Oct 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20261014/27183634.html

Eton and Aquestive strike U.S. deal for diazepam buccal film

Wed, 14 Oct 2026 06:51:35 -0400

Eton Pharmaceuticals (Nasdaq: ETON) and Aquestive Therapeutics (Nasdaq: AQST) have entered into an exclusive U.S. licensing and supply agreement for Libervant (diazepam) buccal film, a treatment for seizure clusters in epilepsy patients, according to a joint press release dated Oct. 14, 2026.

Under the agreement, Eton receives exclusive U.S. commercialization rights to Libervant, a buccal film that dissolves inside the cheek without a delivery device. The product carries Orphan Drug Designation and has tentative FDA approval for patients ages 2 to 5 and 12 and older. A separate application to expand the label to include patients ages 6 to 11 carries

Eton and Aquestive strike U.S. deal for diazepam buccal film

Wed, 14 Oct 2026 06:51:35 -0400

Eton and Aquestive strike U.S. deal for diazepam buccal film

Wed, 14 Oct 2026 06:51:35 -0400

Eton and Aquestive strike U.S. deal for diazepam buccal film

Wed, 14 Oct 2026 06:51:35 -0400

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Wed, 14 Oct 2026 06:50:00 -0400

Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.
Patient market research demonstrated strong preference for buccal film, with 71% of surveyed patients preferring film versus 13% for nasal spray, assuming equivalent efficacy
Anticipated commercial launch in April 2027, subject to final FDA approval, provides a potential near-term growth opportunity and new commercial platform in neurology
LIBERVANT has received Orphan Drug Designation and has issued patent protection extending into 2038, with additional patent applications pending with the U.S. Patent and Trademark

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Wed, 14 Oct 2026 06:50:00 -0400

Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.
Patient market research demonstrated strong preference for buccal film, with 71% of surveyed patients preferring film versus 13% for nasal spray, assuming equivalent efficacy
Anticipated commercial launch in April 2027, subject to final FDA approval, provides a potential near-term growth opportunity and new commercial platform in neurology
LIBERVANT has received Orphan Drug Designation and has issued patent protection extending into 2038, with additional patent applications pending with the U.S. Patent and Trademark

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Wed, 14 Oct 2026 06:50:00 -0400

Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.
Patient market research demonstrated strong preference for buccal film, with 71% of surveyed patients preferring film versus 13% for nasal spray, assuming equivalent efficacy
Anticipated commercial launch in April 2027, subject to final FDA approval, provides a potential near-term growth opportunity and new commercial platform in neurology
LIBERVANT has received Orphan Drug Designation and has issued patent protection extending into 2038, with additional patent applications pending with the U.S. Patent and Trademark

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Wed, 14 Oct 2026 06:50:00 -0400

Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.
Patient market research demonstrated strong preference for buccal film, with 71% of surveyed patients preferring film versus 13% for nasal spray, assuming equivalent efficacy
Anticipated commercial launch in April 2027, subject to final FDA approval, provides a potential near-term growth opportunity and new commercial platform in neurology
LIBERVANT has received Orphan Drug Designation and has issued patent protection extending into 2038, with additional patent applications pending with the U.S. Patent and Trademark

Form SCHEDULE 13G Aquestive Therapeutics, Filed by: Bass Edward P

Wed, 07 Oct 2026 15:47:00 -0400

si-local-file:///var/storage/secattach/20261007/27161097.html

Form SCHEDULE 13G/A Aquestive Therapeutics, Filed by: BRATTON DOUGLAS K

Wed, 07 Oct 2026 14:14:00 -0400

si-local-file:///var/storage/secattach/20261007/27160649.html

Form 8-K Aquestive Therapeutics, For: Sep 29

Tue, 29 Sep 2026 07:22:00 -0400

si-local-file:///var/storage/secattach/20260929/27117367.html

Aquestive Therapeutics names Richard Daly to its board of directors

Tue, 29 Sep 2026 07:02:02 -0400

Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced the appointment of Richard Daly to its board of directors, effective October 14, 2026, according to a company press release.

Daly brings more than 30 years of experience in the pharmaceutical industry, having held senior roles at AstraZeneca, Takeda Pharmaceutical Company, and Catalyst Pharmaceuticals, Inc. He currently serves as President of Global Rare Disease at Angelini Pharma S.p.A., following Angelini's acquisition of Catalyst Pharmaceuticals, where he served as President and Chief Executive Officer.

Earlier roles included Executive Vice President, Americas at Takeda, where he directed the integration of TAP Pharmaceuticals into Takeda, and President of the

Aquestive Therapeutics names Richard Daly to its board of directors

Tue, 29 Sep 2026 07:02:02 -0400

Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced the appointment of Richard Daly to its board of directors, effective October 14, 2026, according to a company press release.

Earlier roles included Executive Vice President, Americas at Takeda, where he directed the integration of TAP Pharmaceuticals into Takeda, and President of the

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Tue, 29 Sep 2026 07:00:00 -0400

Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors

WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Rich Daly to the Company’s Board of Directors, effective October 14, 2026. Mr. Daly has three decades of leadership experience in large and small biopharmaceutical

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Tue, 29 Sep 2026 07:00:00 -0400